This Study Aims to Quantify Decisional Regret as Well as Quality of Life in Patients With Low- to High-risk Cancer and High Burden of Symptoms Undergoing Radiotherapy Using Established Questionnaires.

In this prospective registry study, patients with low-, intermediate- and high-risk tumor entities as well as patients with high symptom burden of any tumor entity in palliative constellation with indication for radiation treatment are included. This radiation treatment can be applied either as 3D-conformal RT or IGRT. The duration of treatment can range from one day to several weeks. For the primary endpoint as well as the secondary clinical and other exploratory endpoints, the 3 groups will be compared in terms of DR, QoL, toxicities and treatment plan parameters

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Quality of Life (QOL) Decision Making ,Shared

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Decisional regret and quality of life are quantified and analyzed using general linear models (e.g. linear regression models, ANOVA), taking into account covariates such as tumor stage, application of further systemic therapies, extent of the radiation area, occurrence of acute and/or late side effects. Survival time analyses and tumor control rates are evaluated using Kaplan- Meyer and Cox regression. Technical endpoints, quality of life and patient satisfaction will be described descriptively and compared between the cohorts using a mixed linear model.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Indication for radiotherapy
Patient information and declaration of consent
Patients age ≥ 18 years

Exclusion criteria

previous radiotherapy in affected site or same localisation in group 1-3
Inability to answer the questionnaires
Pre-existing conditions with increased risk of acute or late toxicity (LiFraumeni, Crohn's disease, ulcerative colitis)
Simultaneous participation in other studies that could interfere with this study and/or participation before expiry of a required restriction period
Persons who are in a dependent/employment relationship with the investigator

Treatment and study plan

Primary outcomes

Decisional Regret

Time frame: from enrollment to the end of routinely performed clinical follow-up examinations after 5 yeasr after RT start

Decisional Regret (DR) is measured by the German version of the Ottawa Decisional Regret Scale (Rühle et al. 2014) by answering the comprising 5 questions. Responses are provided on a five-point Likert scale. Decision regret is categorized as absent (0 points), mild (1-25 points) and strong (>25 points).
Quality of Life after Radiotherapy

Time frame: from enrollment to the end of routinely performed clinical follow-up examinations after 5 yeasr after RT start

Quality of Life is measured using the 80 question comprising PRO-CTCAE questionnaire version 1.0 (Hagelstein et al 2016) , the 30 question comprising EORTC QLQC30 questionnaire version 3.0 and the PSQ-18 questionnaire (Thayaparan and Mahdi 2013). All questionnaires have been previously validated in other publications.

Sponsors and collaborators

Lead sponsor

University Medical Center Goettingen

Other

Registry information

Official study title

Decisional Regret Following Radiotherapy Against Cancer With Poor to Excellent Prognosis

Acronym: DoItAgain

Important dates

Study start: 2025
Primary completion: 2029
Study completion: 2032
First posted: Apr 10, 2025
Registry last updated: Apr 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting